Edward M. Kaye, M.D.

Chief Executive Officer

Ed Kaye is the Chief Executive Officer and a Director of Stoke Therapeutics. Ed served as President and Chief Executive Officer of Sarepta Therapeutics (NASDAQ: SRPT) from September 2016 to June 2017, interim Chief Executive Officer from March 2015 to September 2016, and Chief Medical Officer from June 2011 to April 2017. He also served on the Company’s Board of Directors. Previously, Ed was Group Vice President of Clinical Development at Genzyme Corporation from April 2007 to June 2011, where he supervised the clinical research in the lysosomal storage disease programs and in the genetic neurological disorders. Prior to this, Dr. Kaye held various roles at Genzyme Corporation since 2001, including Vice President of Medical Affairs for Lysosomal Storage Diseases, Vice President of Clinical Research and Interim Head of PGH Global Medical Affairs. Ed currently serves as a member of the Boards of Directors of Cytokinetics, Inc. and The Massachusetts Biotechnology Council.

Prior to entering the biotech industry, Ed trained in Pediatrics, Pediatric Neurology, and Biochemical Genetics. He was on the research staff of the Massachusetts General Hospital, Tufts University Medical Center and was the Chief of Biochemical Genetics at the Children’s Hospital of Philadelphia. He continues on staff in Pediatric Neurology at the Boston Children’s Hospital. Ed earned his B.S. in Biology from Loyola University and earned his M.D. at Loyola University Stritch School of Medicine.

Huw M. Nash, Ph.D.

Chief Operating Officer and Chief Business Officer

Huw Nash is the Chief Operating Officer and Chief Business Officer of Stoke Therapeutics, and previously was the founding Chief Executive Officer. An Entrepreneur-in-Residence at Apple Tree Partners focused on novel therapeutics, Huw has 20 years of experience establishing, funding and growing start-up biotechnology companies. Prior to Stoke, Huw was a co-founder and Vice President of Corporate Development for Aileron Therapeutics (NASDAQ: ALRN). He was also a founding scientist of NeoGenesis Pharmaceuticals, where he served as Vice President of External Collaborations prior to the company’s acquisition by Schering-Plough. Huw received his B.A. in Biochemical Sciences from Harvard College and received his Ph.D. in Organic Chemistry from Harvard University.

Barry Ticho, M.D., Ph.D., FACC

Chief Medical Officer

Barry Ticho is the Chief Medical Officer at Stoke Therapeutics, where he is helping to lead the company’s efforts to develop first-in-class therapeutics to treat rare diseases. Prior to joining Stoke, Barry was Head of Development of mRNA treatments for Cardiovascular and Metabolic Diseases at Moderna Therapeutics. Previously, he was Head of External R&D Innovation for Cardiovascular and Metabolic Diseases at Pfizer, and prior to that he was Vice President of Clinical Development at Biogen. Barry obtained his M.D. and Ph.D. degrees from the University of Chicago and completed pediatrics training at Northwestern University and a cardiology fellowship at Children’s Hospital in Boston. He was on clinical staff at Harvard Medical School and Massachusetts General Hospital and conducted laboratory research on the regulation of cardiac development.

Gene Liau, Ph.D.

EVP, Head of Research & Preclinical Development

Gene Liau is the Executive Vice President; Head, Research and Preclinical Development at Stoke Therapeutics.  Gene previously served as Senior Vice President and Head of Gene Therapy R&D at Precision BioSciences from 2015-2017. From 2011-2015 he was at Pfizer where, as Executive Director, he led External R&D efforts for Rare Disease and Hematology and spearheaded the Pfizer Gene Therapy initiative.  Prior to Pfizer, he helped Shire build an innovative rare disease portfolio. Gene was at Novartis for twelve years, initially building a Research Unit focused on using gene therapy for cardiovascular and metabolic applications and eventually leading the cardiovascular/metabolic division at the Novartis Institutes for BioMedical Research in Cambridge where he was responsible for projects from target discovery to early clinical PoC. Prior to entering industry, Gene was a Professor at George Washington University Medical Center and also a Senior Scientist at the Jerome H. Holland Laboratory of the American Red Cross.  Gene received his Ph.D. in Biochemistry from Vanderbilt University and did his Postdoctoral Fellowship at the National Cancer Institute.

Isabel Aznarez, Ph.D.

Co-Founder and Vice President, Head of Biology

Isabel Aznarez is a co-founder and Vice President of Biology of Stoke Therapeutics. Isabel has extensive experience in human genetics, RNA metabolism, and modulation of RNA processes using antisense oligonucleotides. Prior to founding Stoke Therapeutics, she was a Research Investigator with Prof. Adrian Krainer, whose lab she joined as a postdoctoral fellow in 2008. Previously, Isabel was a researcher at the Hospital for Sick Children with Prof. Lap-Chee Tsui, where she focused on the effect of cystic fibrosis mutations on the splicing of the CFTR gene. Isabel holds a Ph.D. in Medical & Molecular Genetics from the University of Toronto (2006), and a B.Sc. in Biology and Human Genetics from the University of Uruguay.

Charles R. Allerson, Ph.D.

Vice President of Chemistry

Chuck Allerson is the Vice President of Chemistry for Stoke Therapeutics. A career nucleoside/oligonucleotide chemist, Chuck has over 15 years’ experience in the design and development of oligonucleotide therapeutics for antisense, RNAi and microRNA targeting applications. Most recently, Chuck was Director of Chemistry for Regulus Therapeutics, and prior to that held roles of increasing responsibility at Ionis Pharmaceuticals and Variagenics. Chuck holds a Ph.D. in organic chemistry from Harvard University, where he studied with Professor Gregory Verdine, and was a post-doctoral researcher at the National Institutes of Health where he worked with Dr. Tracey A. Rouault, M.D.

Meena, Ph.D.

Vice President of Bioanalytical, DMPK and Biomarker Development

Meena is the Vice President of Bioanalytical, DMPK and Biomarker Development at Stoke Therapeutics. Meena brings 20 years of experience in nucleic acids therapeutics to Stoke. Prior to joining Stoke, Meena served as Senior Director of Bioanalytical, Pharmacology and Biomarker Development at Wave Life Sciences. In her eight years at Wave (formerly Ontorii) and as its first employee, Meena played a pivotal role in building the company’s stereopure oligonucleotide chemistry platform and helping to guide the clinical entry of three antisense programs. Before joining Wave, Meena worked at Alnylam Pharmaceuticals on siRNA chemistry and targeted siRNA delivery. Meena received her Ph.D. in Chemistry with Dr. K.N. Ganesh at the National Chemical Laboratory in Pune, India and did her post-doctoral research on nucleic acids analogues with Prof. Larry W. McLaughlin at Boston College.

Shamim Ruff

Senior Vice President of Regulatory Affairs and Quality

Shamim Ruff is the Senior Vice President of Regulatory Affairs and Quality at Stoke Therapeutics. Ruff has extensive knowledge of drug development with more than 25 years in the biopharmaceutical industry, working with a diverse range of therapeutics including small molecules, monoclonal antibodies, oncolytic viruses and oligonucleotides. Her expertise in both domestic and international regulatory affairs spans early and late development across multiple therapeutic areas. Prior to joining Stoke, she was at Sarepta Therapeutics, where she built the company’s regulatory affairs and quality organizations and was responsible for leading and defining the regulatory strategy for their rare and infectious disease pipelines. Prior to joining Sarepta, Ruff served as Vice President, Head of Regulatory Affairs Oncology at Sanofi-Genzyme, where she was responsible for leading the Global, European and CMC Regulatory Affairs teams. She previously held senior positions at Amgen, Abbott and AstraZeneca where she had global oversight for the development and filings of multiple successful regulatory approvals. Ruff holds a BSc. in chemistry & biology from the University of Leicester, UK, and an MSc. in analytical chemistry from the University of Loughborough, UK. Additionally, she is a Chartered Chemist and Member of the Royal Society of Chemistry (CChem MRSC), and is also a member of DIA, RAPS, ASCO and ASGCT.

Nancy Wyant

Vice President, Head of Clinical Operations

Nancy Wyant is Vice President, Head of Clinical Operations at Stoke Therapeutics. Wyant has been an independent consultant since February 2018 and during that time has collaborated with Stoke on several key projects. Previously, she was Vice President, Clinical Operations at BeiGene USA, Inc, where she helped build the global clinical operations organization, implemented compliance standards and oversaw global clinical trial execution. Throughout her career, Wyant has led clinical trial development operations across the biotechnology industry, including as Vice President, Clinical Operations at Idera Pharmaceuticals, as Head of Clinical Operations at Sarepta Therapeutics and as Head of Global Clinical Operations at Shire Human Genetic Therapies. She also facilitated clinical operations and clinical compliance programs at EMD Serono, Therion Biologics Corporation and Vertex Pharmaceuticals. Wyant began her career at Massachusetts General Hospital as a Clinical Research and Program Coordinator. She is a member of Linking Leaders Boston and the American Epilepsy Society as well as the Society for Clinical Oncology and has a B.A. in psychology from Hartwick College.

Edward M. Kaye, M.D.

CEO and Director

Ed Kaye is the Chief Executive Officer and a Director of Stoke Therapeutics. Ed served as President and Chief Executive Officer of Sarepta Therapeutics (NASDAQ: SRPT) from September 2016 to June 2017, interim Chief Executive Officer from March 2015 to September 2016, and Chief Medical Officer from June 2011 to April 2017. He also served on the Company’s Board of Directors. Previously, Ed was Group Vice President of Clinical Development at Genzyme Corporation from April 2007 to June 2011, where he supervised the clinical research in the lysosomal storage disease programs and in the genetic neurological disorders. Prior to this, Dr. Kaye held various roles at Genzyme Corporation since 2001, including Vice President of Medical Affairs for Lysosomal Storage Diseases, Vice President of Clinical Research and Interim Head of PGH Global Medical Affairs. Ed currently serves as a member of the Boards of Directors of Cytokinetics, Inc. and The Massachusetts Biotechnology Council.

Prior to entering the biotech industry, Ed trained in Pediatrics, Pediatric Neurology, and Biochemical Genetics. He was on the research staff of the Massachusetts General Hospital, Tufts University Medical Center and was the Chief of Biochemical Genetics at the Children’s Hospital of Philadelphia. He continues on staff in Pediatric Neurology at the Boston Children’s Hospital. Ed earned his B.S. in Biology from Loyola University and earned his M.D. at Loyola University Stritch School of Medicine.

Adrian Krainer, Ph.D.

Co-founder and Director

Adrian R. Krainer is a co-founder and Director of Stoke Therapeutics, and is the St. Giles Professor of Molecular Genetics and Program Chair of Cancer and Molecular Biology at Cold Spring Harbor Laboratory. Prof. Krainer’s fundamental and applied research on RNA splicing for over three decades directly led to the invention and development of SPINRAZA^TM (nusinersen), the first approved therapeutic that corrects a splicing defect, and a life-saving drug for infants with spinal muscular atrophy. He is a member of the American Academy of Arts and Sciences, a Pew Scholar in the Biomedical Sciences, and a recipient of an NIH MERIT award and New York Intellectual Property Law Association’s 2017 inventor-of-the-year award.

Arthur A. Levin, Ph.D.

Director

Art Levin is a Director of Stoke Therapeutics and has an unparalleled track record and reputation in the field of nucleic acid-based therapeutics. He currently serves as Executive Vice President, Research and Development at Avidity Biosciences. Previously he held that position at miRagen Therapeutics. Prior to that he held senior drug development roles at Ionis Pharmaceuticals and Santaris Pharma. He has played key roles in the development of numerous of oligonucleotides including the first approved antisense NDAs, and the first microRNA-targeted therapeutic in clinical trials. He has a combined three decades of experience in all aspects of drug development from discovery through drug registration, both in large pharma and biotech companies. Art has published over 60 scientific articles and several of the most cited reviews in the field. He serves as a director of the Oligonucleotide Therapeutics Society and holds several additional scientific organization affiliations and honors. He received a doctorate in toxicology from the University of Rochester, and a bachelor’s degree in biology from Muhlenberg College.

Seth L. Harrison, M.D.

Chairman

Seth Harrison is the founder and managing partner of Apple Tree Partners (ATP) and is Chairman of the Board of Directors of Stoke Therapeutics. He has invested in life sciences since 1991. He is also currently Chairman of ATP companies Braeburn Pharmaceuticals, Elstar Therapeutics, Limelight Bio, and Syntimmune, and is a Director of Corvidia Therapeutics.

Seth’s prior investments include: Aileron Therapeutics, ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, HeartWare International, Informed Access, SGX Pharmaceuticals, Tokai Pharmaceuticals, Ultracision, and ViroPharma. From 2002 to 2010, he also served on the board of the International Partnership for Microbicides. Prior to founding ATP in 1999, Seth was a general partner at Oak Investment Partners, and before that a venture partner at Sevin Rosen Funds.

Seth received an A.B. from Princeton University, an M.D. and M.B.A. both from Columbia University, and completed a surgery internship at the Presbyterian Hospital in the City of New York.

Samuel W. Hall, Ph.D.

Director

Sam Hall is a principal at Apple Tree Partners (ATP) and is a Director of Stoke Therapeutics. Prior to joining ATP in 2013, Sam was a researcher at the University of Cambridge in the U.K., where his work focused on novel therapeutic strategies for autoimmune diseases. Previously, Sam was a member of the investment team at Symphony Capital, a private equity firm dedicated to investments in biopharmaceutical development. Prior to Symphony, he served as a member of the healthcare investment banking team at Citigroup, where he advised leading biotechnology, medical device and healthcare services businesses on numerous completed strategic and debt and equity financing engagements.

Sam holds an A.B. in Molecular Biology from Princeton University and completed his M.Phil. and Ph.D. research at the University of Cambridge, where he was a Taylor Research Scholar and was awarded an NSF Graduate Research Fellowship for his work.

In addition to Stoke Therapeutics, Sam is on the Board of Directors of Syntimmune, Elstar Therapeutics and Limelight Bio.

Arthur Tzianabos, Ph.D.

Director

Dr. Arthur Tzianabos is the president and CEO of Homology Medicines. At Homology, Dr. Tzianabos leads efforts to develop genetic medicines by leveraging its in vivo gene therapy and nuclease-free gene editing platform for patients with rare genetic diseases. He previously served as president and CSO of OvaScience, where he translated early science into treatments for fertility patients. Dr. Tzianabos also spent nine years at Shire, where he worked on the development and launches of multiple treatments for patients with rare genetic disorders and worked closely with the business development team to build Shire’s product pipeline through investments and acquisitions. Earlier in his career, Dr. Tzianabos was a principal investigator and faculty member at Harvard Medical School for 15 years, reaching the rank of associate professor of medicine and maintaining laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. Dr. Tzianabos has published more than 80 scientific papers, reviews, book chapters and patents. He is a member of the board of directors for gene therapy company Akouos and serves on the development board for the University of New Hampshire’s College of Life Sciences and Agriculture. Dr. Tzianabos holds a B.S. in biology from Boston College and a Ph.D. in microbiology from the University of New Hampshire.